Analysts expect RA Medical Systems Inc (NYSE:RMED) to post $3.38 million in sales for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for RA Medical Systems’ earnings, with estimates ranging from $2.92 million to $3.83 million. The company is scheduled to announce its next earnings report on Tuesday, February 12th.
On average, analysts expect that RA Medical Systems will report full-year sales of $7.78 million for the current year, with estimates ranging from $7.19 million to $8.37 million. For the next financial year, analysts anticipate that the business will post sales of $38.90 million, with estimates ranging from $38.54 million to $39.25 million. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that follow RA Medical Systems.
RA Medical Systems (NYSE:RMED) last posted its quarterly earnings results on Tuesday, November 13th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.23). The firm had revenue of $2.06 million for the quarter, compared to the consensus estimate of $2.19 million.
A number of research firms recently weighed in on RMED. Cantor Fitzgerald set a $21.00 target price on shares of RA Medical Systems and gave the stock a “buy” rating in a report on Wednesday, November 14th. Maxim Group began coverage on shares of RA Medical Systems in a report on Friday, November 2nd. They set a “buy” rating and a $23.00 target price on the stock. SunTrust Banks began coverage on shares of RA Medical Systems in a report on Monday, October 22nd. They set a “buy” rating and a $16.00 target price on the stock. Finally, Piper Jaffray Companies began coverage on shares of RA Medical Systems in a report on Monday, October 22nd. They set an “overweight” rating and a $23.00 target price on the stock.
Shares of NYSE RMED traded up $0.21 during midday trading on Friday, hitting $8.00. The company’s stock had a trading volume of 552 shares, compared to its average volume of 84,763. RA Medical Systems has a one year low of $7.50 and a one year high of $22.00.
A number of institutional investors have recently bought and sold shares of the stock. Neuberger Berman Group LLC bought a new stake in RA Medical Systems during the 3rd quarter worth approximately $4,550,000. Thrivent Financial for Lutherans bought a new stake in RA Medical Systems during the 3rd quarter worth approximately $1,838,000. Putnam Investments LLC bought a new stake in RA Medical Systems during the 3rd quarter worth approximately $1,856,000. Point72 Asset Management L.P. bought a new stake in RA Medical Systems during the 3rd quarter worth approximately $1,219,000. Finally, Sio Capital Management LLC bought a new stake in RA Medical Systems during the 3rd quarter worth approximately $2,467,000. 9.87% of the stock is currently owned by institutional investors and hedge funds.
RA Medical Systems Company Profile
Ra Medical Systems, Inc, a commercial-stage medical device company, develops, manufactures, and markets excimer lasers for use in the treatment of vascular and dermatological diseases. The company offers DABRA (destruction of arteriosclerotic blockages by laser radiation ablation), a minimally-invasive excimer laser and disposable catheter system that is used by physicians in the endovascular treatment of vascular blockages resulting from lower extremity vascular disease.
Recommended Story: Hedge Funds
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for RA Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RA Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.